Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17189706
Blonska M, et al. (2007) The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in the T cell receptor-signaling pathway. Immunity 26, 55-66 17189706
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  JPM50.6 (T lymphocyte), Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  50.6 WT cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-CD3/CD28 increase Jurkat
anti-CD3/CD28 CARD11 (human) no effect upon treatment-induced increase JPM50.6 (CARD11-deficient)
phorbol_ester, ionomycin increase Jurkat
ionomycin, phorbol_ester CARD11 (human) no effect upon treatment-induced increase JPM50.6 (CARD11-deficient)

Y204-p - ERK1 (human)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  JPM50.6 (T lymphocyte), Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  50.6 WT cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-CD3/CD28 increase Jurkat
anti-CD3/CD28 CARD11 (human) no effect upon treatment-induced increase JPM50.6 (CARD11-deficient)
phorbol_ester, ionomycin increase Jurkat
ionomycin, phorbol_ester CARD11 (human) no effect upon treatment-induced increase JPM50.6 (CARD11-deficient)

T185-p - ERK2 (human)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  JPM50.6 (T lymphocyte), Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  50.6 WT cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-CD3/CD28 increase Jurkat
anti-CD3/CD28 CARD11 (human) no effect upon treatment-induced increase JPM50.6 (CARD11-deficient)
phorbol_ester, ionomycin increase Jurkat
ionomycin, phorbol_ester CARD11 (human) no effect upon treatment-induced increase JPM50.6 (CARD11-deficient)

Y187-p - ERK2 (human)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  JPM50.6 (T lymphocyte), Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  50.6 WT cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-CD3/CD28 increase Jurkat
anti-CD3/CD28 CARD11 (human) no effect upon treatment-induced increase JPM50.6 (CARD11-deficient)
phorbol_ester, ionomycin increase Jurkat
ionomycin, phorbol_ester CARD11 (human) no effect upon treatment-induced increase JPM50.6 (CARD11-deficient)

S32-p - IkB-alpha (human)
Modsite: LLDDRHDsGLDSMKD SwissProt Entrez-Gene
Orthologous residues
IkB‑alpha (human): S32‑p, IkB‑alpha (mouse): S32‑p, IkB‑alpha (rat): S32‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  JPM50.6 (T lymphocyte), Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  50.6 WT cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-CD3/CD28 augment treatment-induced decrease JPM50.6 (CARD11-deficient)
cycloheximide anti-CD3/CD28 inhibit treatment-induced increase JPM50.6 (CARD11-deficient)
MG132 anti-CD3/CD28 augment treatment-induced increase JPM50.6 (CARD11-deficient)
actinomycin_D anti-CD3/CD28 inhibit treatment-induced increase JPM50.6 (CARD11-deficient)
MG132, actinomycin_D anti-CD3/CD28 augment treatment-induced increase JPM50.6 (CARD11-deficient)

S36-p - IkB-alpha (human)
Modsite: RHDSGLDsMKDEEYE SwissProt Entrez-Gene
Orthologous residues
IkB‑alpha (human): S36‑p, IkB‑alpha (mouse): S36‑p, IkB‑alpha (rat): S36‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  JPM50.6 (T lymphocyte), Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  50.6 WT cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-CD3/CD28 augment treatment-induced decrease JPM50.6 (CARD11-deficient)
cycloheximide anti-CD3/CD28 inhibit treatment-induced increase JPM50.6 (CARD11-deficient)
MG132 anti-CD3/CD28 augment treatment-induced increase JPM50.6 (CARD11-deficient)
actinomycin_D anti-CD3/CD28 inhibit treatment-induced increase JPM50.6 (CARD11-deficient)
MG132, actinomycin_D anti-CD3/CD28 augment treatment-induced increase JPM50.6 (CARD11-deficient)

T183-p - JNK1 (human)
Modsite: AGTSFMMtPYVVTRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  JPM50.6 (T lymphocyte), Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  50.6 WT cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-CD3/CD28 increase Jurkat
anti-CD3/CD28 CARD11 (human) no effect upon treatment-induced increase JPM50.6 (CARD11-deficient)
phorbol_ester, ionomycin increase Jurkat
ionomycin, phorbol_ester CARD11 (human) no effect upon treatment-induced increase JPM50.6 (CARD11-deficient)
sorbitol increase JPM50.6 (CARD11 deficient) and 50.6 WT (CARD11+)

Y185-p - JNK1 (human)
Modsite: TSFMMTPyVVTRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  JPM50.6 (T lymphocyte), Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  50.6 WT cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-CD3/CD28 increase Jurkat
anti-CD3/CD28 CARD11 (human) no effect upon treatment-induced increase JPM50.6 (CARD11-deficient)
phorbol_ester, ionomycin increase Jurkat
ionomycin, phorbol_ester CARD11 (human) no effect upon treatment-induced increase JPM50.6 (CARD11-deficient)
sorbitol increase JPM50.6 (CARD11 deficient) and 50.6 WT (CARD11+)

T183-p - JNK2 (human)
Modsite: ACTNFMMtPYVVTRY SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  JPM50.6 (T lymphocyte), Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  50.6 WT cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-CD3/CD28 increase Jurkat
anti-CD3/CD28 CARD11 (human) inhibit treatment-induced increase JPM50.6 (CARD11-deficient)
phorbol_ester, ionomycin increase Jurkat
ionomycin, phorbol_ester CARD11 (human) inhibit treatment-induced increase JPM50.6 (CARD11-deficient)
sorbitol increase JPM50.6 (CARD11 deficient) and 50.6 WT (CARD11+)

Y185-p - JNK2 (human)
Modsite: TNFMMTPyVVTRYYR SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  JPM50.6 (T lymphocyte), Jurkat (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  50.6 WT cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-CD3/CD28 increase Jurkat
anti-CD3/CD28 CARD11 (human) inhibit treatment-induced increase JPM50.6 (CARD11-deficient)
phorbol_ester, ionomycin increase Jurkat
ionomycin, phorbol_ester CARD11 (human) inhibit treatment-induced increase JPM50.6 (CARD11-deficient)
sorbitol increase JPM50.6 (CARD11 deficient) and 50.6 WT (CARD11+)

T203-p - ERK1 (mouse)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  B lymphocyte-spleen, mast-bone marrow, T lymphocyte-lymph node
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester, ionomycin increase
ionomycin, phorbol_ester CARD11 (mouse) no effect upon treatment-induced increase homozygous null
ionomycin, phorbol_ester Bcl-10 (mouse) no effect upon treatment-induced increase homozygous null

Y205-p - ERK1 (mouse)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  B lymphocyte-spleen, mast-bone marrow, T lymphocyte-lymph node
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester, ionomycin increase
ionomycin, phorbol_ester CARD11 (mouse) no effect upon treatment-induced increase homozygous null
ionomycin, phorbol_ester Bcl-10 (mouse) no effect upon treatment-induced increase homozygous null

T183-p - ERK2 (mouse)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  B lymphocyte-spleen, mast-bone marrow, T lymphocyte-lymph node
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester, ionomycin increase
ionomycin, phorbol_ester CARD11 (mouse) no effect upon treatment-induced increase homozygous null
ionomycin, phorbol_ester Bcl-10 (mouse) no effect upon treatment-induced increase homozygous null

Y185-p - ERK2 (mouse)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  B lymphocyte-spleen, mast-bone marrow, T lymphocyte-lymph node
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester, ionomycin increase
ionomycin, phorbol_ester CARD11 (mouse) no effect upon treatment-induced increase homozygous null
ionomycin, phorbol_ester Bcl-10 (mouse) no effect upon treatment-induced increase homozygous null

T183-p - JNK1 (mouse)
Modsite: AGTSFMMtPYVVTRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  B lymphocyte-spleen, mast-bone marrow, T lymphocyte-lymph node
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester, ionomycin increase
ionomycin, phorbol_ester CARD11 (mouse) no effect upon treatment-induced increase homozygous null
ionomycin, phorbol_ester Bcl-10 (mouse) no effect upon treatment-induced increase homozygous null

Y185-p - JNK1 (mouse)
Modsite: TSFMMTPyVVTRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  B lymphocyte-spleen, mast-bone marrow, T lymphocyte-lymph node
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester, ionomycin increase
ionomycin, phorbol_ester CARD11 (mouse) no effect upon treatment-induced increase homozygous null
ionomycin, phorbol_ester Bcl-10 (mouse) no effect upon treatment-induced increase homozygous null

T183-p - JNK2 (mouse)
Modsite: ACTNFMMtPYVVTRY SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  B lymphocyte-spleen, mast-bone marrow, T lymphocyte-lymph node
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester, ionomycin increase
ionomycin, phorbol_ester CARD11 (mouse) inhibit treatment-induced increase homozygous null
ionomycin, phorbol_ester Bcl-10 (mouse) inhibit treatment-induced increase homozygous null

Y185-p - JNK2 (mouse)
Modsite: TNFMMTPyVVTRYYR SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  B lymphocyte-spleen, mast-bone marrow, T lymphocyte-lymph node
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester, ionomycin increase
ionomycin, phorbol_ester CARD11 (mouse) inhibit treatment-induced increase homozygous null
ionomycin, phorbol_ester Bcl-10 (mouse) inhibit treatment-induced increase homozygous null